貴州百靈(002424.SZ)：獲得2021年度中醫藥科學技術研究專項課題立項
格隆匯 2 月 19日丨貴州百靈(002424.SZ)公佈，公司於2021年2月19日收到貴州省中醫藥管理局下發《關於轉發<國家中醫藥管理局關於下達2021年度中醫藥科學技術研究專項課題立項計劃的通知>的通知》(黔中醫藥函[2021]17號)，根據《國家中醫藥管理局關於下達2021年度中醫藥科學技術研究專項課題立項計劃的通知》(國中醫藥科技函[2021]18號)，公司“苗藥糖寧通絡片防治糖尿病及視網膜併發症的多中心臨牀研究和機制探討”課題(課題編號：GZY-KJS-2021-006)已獲立項支持，要求公司與廈門大學附屬第一醫院進一步優化課題實施方案，加強課題管理，嚴格遵守生物安全和科研倫理等規定，按照課題任務書相關內容做好課題研究，保障課題實施質量，並及時將課題進展情況向貴州省中醫藥管理局彙報。
此次課題的研究是在貴州百靈中醫糖尿病醫院多年來對糖尿病併發症治療的臨牀觀察效果的基礎上，結合前期中國醫學科學院、香港大學等對糖寧通絡大量臨牀前研究成果，以及中國人民解放軍總醫院臨牀研究結果，完善糖寧通絡對治療糖尿病及併發症真實世界療效的臨牀循證研究。項目由中華中醫藥學會糖尿病分會主任委員、廈門大學附屬第一醫院楊叔禹教授為課題負責人，臨牀研究方案由復旦大學附屬中山醫院李小英教授、中國中醫科學院廣安門醫院倪青教授、成都中醫藥大學附屬銀海眼科醫院段俊國教授等十餘位糖尿病領域權威專家共同參與設計，採用目前國際公認的“隨機、雙盲、多中心、安慰劑對照”的研究方式，評價公司研發的苗藥新制劑“糖寧通絡片”對糖尿病視網膜病變(DR)和糖尿病危險因素控制的臨牀研究，項目將邀請國內多家知名綜合及中醫醫院共同參與完成。旨在為治療糖尿病併發症探尋中醫藥的有效藥物，為糖寧通絡今後研究指引方向，揭示糖寧通絡在治療糖尿病及併發症的藥理和臨牀價值開展深度研究。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
